AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22811447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten weeks of home-based occupational therapy according to the Dutch guidelines of occupational therapy in Parkinson's disease
Number of subjects: 43
Study 22811447 — intervention group
Group type: COMPARATOR
Intervention: No occupational therapy
Number of subjects: 43
Study 20564923 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan and ivabradine
Number of subjects: 41
Study 20564923 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 41
Study 18982536 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-nicotine cigarettes (0.6 mg nicotine)
Number of subjects: 32
Study 18982536 — intervention group
Group type: COMPARATOR
Intervention: Low/zero-nicotine cigarettes (0.05 mg nicotine)
Number of subjects: 32
Study 18982536 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke (medium-nicotine)
Number of subjects: 32
Study 18982536 — intervention group
Group type: COMPARATOR
Intervention: Secondhand smoke (low/zero-nicotine)
Number of subjects: 32
Study 16567056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) advertising
Number of subjects: 718
Study 16567056 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyban advertising
Number of subjects: 718
Study 16567056 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmaceutical cessation services (Quitline) ads
Number of subjects: 718
Study 16567056 — intervention group
Group type: COMPARATOR
Intervention: Non-cessation messages on sun protection
Number of subjects: 718
Study 12727094 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio assessment
Number of subjects: 12
Study 11292003 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg buprenorphine
Number of subjects: 8
Study 11292003 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine
Number of subjects: 8
Study 11292003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9425409 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 30
Study 9425409 — intervention group
Group type: COMPARATOR
Intervention: Lid taping (Control)
Number of subjects: 30
Study 8084247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Number of subjects: 0
Study 8084247 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 20 mg endovenously every 4 h for the first 12 h and every 6 h for the next 12 h
Number of subjects: 0
Study 3664109 — intervention group
Group type: EXPERIMENTAL
Intervention: Female friend as co-therapist
Number of subjects: 30
Study 3664109 — intervention group
Group type: COMPARATOR
Intervention: Husband as co-therapist
Number of subjects: 30
Study 3664109 — intervention group
Group type: COMPARATOR
Intervention: Husband's depression at 2 months
Number of subjects: 30
Study 3664109 — intervention group
Group type: COMPARATOR
Intervention: Overall effect of husband's depression
Number of subjects: 30
Study 31342247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral access sheath (UAS) used for stone treatment (group-1)
Number of subjects: 338
Study 31342247 — intervention group
Group type: COMPARATOR
Intervention: No ureteral access sheath used (group-2)
Number of subjects: 338
Study 30709839 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day ground flaxseed for 6 weeks
Number of subjects: 252
Study 30709839 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 252
Study 28628622 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 3
Study 28628622 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infection (UTI) status
Number of subjects: 3
Study 25733649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use, lipid-based supplementary food (RUSF)
Number of subjects: 1264
Study 25733649 — intervention group
Group type: EXPERIMENTAL
Intervention: Special corn-soy blend (CSB++)
Number of subjects: 1264
Study 25733649 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally processed, fortified flour (Misola)
Number of subjects: 1264
Study 25733649 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally milled flours plus oil, sugar, and micronutrient powder (LMF)
Number of subjects: 1264
Study 23835431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (16-week session)
Number of subjects: 45
Study 23835431 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or non-exercise)
Number of subjects: 45
Study 21720788 — intervention group
Group type: EXPERIMENTAL
Intervention: P and E2 (4 mg/d)
Number of subjects: 118
Study 21720788 — intervention group
Group type: COMPARATOR
Intervention: P
Number of subjects: 118
Study 19939249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including counselling sessions, courses, and informational packages for 7 months
Number of subjects: 163
Study 16805685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic treatment
Number of subjects: 30
Study 16805685 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment at 160 mJ/pulse at 10 Hz
Number of subjects: 30
Study 16805685 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study 15012723 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 28
Study 15012723 — intervention group
Group type: EXPERIMENTAL
Intervention: basiliximab
Number of subjects: 28
Study 10694836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 747
Study 10694836 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 747
Study 10694836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 747
Study 8970278 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week behavioral medicine support group intervention
Number of subjects: 0
Study 1457626 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (8 mg)
Number of subjects: 30
Study 1457626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6500760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg at 8 a.m.
Number of subjects: 0
Study 6500760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg at 8 p.m.
Number of subjects: 0
Study 6500760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during wash-out period)
Number of subjects: 0
Study 31010875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg once-weekly
Number of subjects: 75
Study 31010875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30033542 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline oral capsules 40 mg (DFD-09) under fed conditions
Number of subjects: 12
Study 30033542 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline oral capsules 40 mg (DFD-09) under fasting conditions
Number of subjects: 12
Study 30033542 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline oral capsules 40 mg (DFD-09)
Number of subjects: 12
Study 27378239 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual follow-up of nonsolid nodules (NSNs) identified by CT screening for lung cancer.
Number of subjects: 2534
Study 24937223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic water filters (CWFs) impregnated with silver nanoparticles
Number of subjects: 74
Study 24937223 — intervention group
Group type: COMPARATOR
Intervention: Control group without filters
Number of subjects: 74
Study 24937223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic water filters (CWFs)
Number of subjects: 74
Study 23101545 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 20
Study 23101545 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 20
Study 23101545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19954772 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety behavior reduction plus exposure (SB + EXP)
Number of subjects: 130
Study 19954772 — intervention group
Group type: COMPARATOR
Intervention: Graduated exposure (EXP)
Number of subjects: 130
Study 17407214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 201
Study 17407214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 201
Study 15887252 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to RF fields emitted by mobile phones
Number of subjects: 0
Study 15887252 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exposure to RFs)
Number of subjects: 0
Study 12411221 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal selegiline (20 mg applied once daily by means of a 20-cm² patch)
Number of subjects: 177
Study 12411221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 12411221 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal selegiline
Number of subjects: 177
Study 10449891 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan in combination with ACE inhibitors and other prescribed therapies
Number of subjects: 0
Study 10449891 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 9275755 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Hypertensives (EH)
Number of subjects: 154
Study 9275755 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive Offspring from Hypertensive Families (SH)
Number of subjects: 154
Study 9275755 — intervention group
Group type: COMPARATOR
Intervention: Normotensive Controls
Number of subjects: 154
Study 9275755 — intervention group
Group type: COMPARATOR
Intervention: Normotensive Families (SN)
Number of subjects: 154
Study 2048958 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prevention interventions (mean number of 7.5 actions)
Number of subjects: 161
Study 2048958 — intervention group
Group type: COMPARATOR
Intervention: Classic surveillance (mean number of 1 action)
Number of subjects: 161
Study 6758224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 104
Study 6758224 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (two-tablet regimen)
Number of subjects: 104
Study 6758224 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (three-tablet regimen)
Number of subjects: 104
Study 31948992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA) operation
Number of subjects: 120
Study 31948992 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 120
Study 31274778 — intervention group
Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc)
Number of subjects: 180
Study 31274778 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dressing securement (SorbaView SHIELD, with prolene sutures and chlorhexidine gluconate disc)
Number of subjects: 180
Study 31274778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (Histoacryl, B Braun) in addition to standard care
Number of subjects: 180
Study 27817915 — intervention group
Group type: EXPERIMENTAL
Intervention: Evicel fibrin glue
Number of subjects: 89
Study 27817915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel fibrin glue
Number of subjects: 89
Study 27817915 — intervention group
Group type: COMPARATOR
Intervention: 10-0 Vicryl sutures
Number of subjects: 89
Study 26212172 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 plus NADH supplementation
Number of subjects: 80
Study 26212172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23152589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 301
Study 23152589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 19574017 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TEAS (transcutaneous electric acupoint stimulation)
Number of subjects: 48
Study 19574017 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 48
Study 19574017 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TEAS
Number of subjects: 48
Study 17852631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (betamethasone-dipropionate cream)
Number of subjects: 14
Study 17852631 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 14
Study 16265633 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study 16265633 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hepatic encephalopathy (HE)
Number of subjects: 11
Study 12100779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 health screenings
Number of subjects: 2000
Study 12100779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 health screenings + 45-minute follow-up consultation annually
Number of subjects: 2000
Study 12100779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health screenings)
Number of subjects: 2000
Study 10417250 — intervention group
Group type: EXPERIMENTAL
Intervention: Word processing
Number of subjects: 0
Study 10417250 — intervention group
Group type: EXPERIMENTAL
Intervention: Object processing
Number of subjects: 0
Study 10417250 — intervention group
Group type: COMPARATOR
Intervention: Words and objects
Number of subjects: 0
Study 10417250 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming words and objects
Number of subjects: 0
Study 7502226 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (platinum-based combination chemotherapy)
Number of subjects: 0
Study 7502226 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 0
Study 2278549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic drug treatments for three months
Number of subjects: 70
Study 2278549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7003032 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 555
Study 7003032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 7003032 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day)
Number of subjects: 555
Study 31122045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of mother-to-child transmission of HIV intervention
Number of subjects: 1399
Study 31122045 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1399
Study 28276148 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle flushing three times with 2 ml in each follicle
Number of subjects: 80
Study 28276148 — intervention group
Group type: COMPARATOR
Intervention: Direct follicle aspiration
Number of subjects: 80
Study 28276148 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle flushing
Number of subjects: 80
Study 24841733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional tetracycline 2% injection
Number of subjects: 11
Study 23238443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid contact lens correction
Number of subjects: 500
Study 21325345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (2891 participants)
Number of subjects: 5804
Study 21325345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2913 participants)
Number of subjects: 5804
Study 18752466 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of evening exercise (1 hour at 60% of VO2 peak)
Number of subjects: 8
Study 18752466 — intervention group
Group type: COMPARATOR
Intervention: Evening rest (control)
Number of subjects: 8
Study 17196795 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs with hormonal therapy (HT)
Number of subjects: 170
Study 17196795 — intervention group
Group type: COMPARATOR
Intervention: SSRIs without hormonal therapy (HT)
Number of subjects: 170
Study 15505441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 6
Study 15505441 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 6
Study 15505441 — intervention group
Group type: COMPARATOR
Intervention: Natural Sleep
Number of subjects: 6
Study 11227936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pressure-volume measurement with a compliant balloon
Number of subjects: 10
Study 11227936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal impedance planimetry
Number of subjects: 10
Study 11227936 — intervention group
Group type: COMPARATOR
Intervention: Pressure-volume measurement with a large, noncompliant bag
Number of subjects: 10
Study 9781630 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after hypoglycemic insulin clamp (1 mU/kg/min)
Number of subjects: 10
Study 9781630 — intervention group
Group type: COMPARATOR
Intervention: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after euglycemic clamp
Number of subjects: 10
Study 7811440 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol reduction intervention (cognitive-behavioral program with six counseling sessions over 3 months)
Number of subjects: 580
Study 7811440 — intervention group
Group type: COMPARATOR
Intervention: Control observation group
Number of subjects: 580
Study 2193774 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodyne-lubricant jelly (ALJ)
Number of subjects: 372
Study 2193774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 372
Study 2193774 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 (ALJ and placebo)
Number of subjects: 372
Study 2193774 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2 (lidocaine and placebo)
Number of subjects: 372
Study 353973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (26 patients)
Number of subjects: 55
Study 353973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (29 patients)
Number of subjects: 55
Study 30526281 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic drug use (either antiplatelets or anticoagulants)
Number of subjects: 817
Study 30526281 — intervention group
Group type: COMPARATOR
Intervention: Delay in surgery after cessation of antiplatelet drug
Number of subjects: 817
Study 30526281 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery and early antithrombotic recommencement
Number of subjects: 817
Study 30531381 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dual-task training
Number of subjects: 121
Study 30531381 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive dual-task training
Number of subjects: 121
Study 28624294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid plus surgeon preference report (decision aid)
Number of subjects: 343
Study 28624294 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 343
Study 26165370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina techniques applied to real acupoints
Number of subjects: 69
Study 26165370 — intervention group
Group type: COMPARATOR
Intervention: Non-specific skin points treatment (Control)
Number of subjects: 69
Study 23844552 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling session on alcohol risk reduction
Number of subjects: 392
Study 23844552 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 392
Study 21999717 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care management intervention
Number of subjects: 499
Study 21999717 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 499
Study 19651998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 0
Study 19651998 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17214754 — intervention group
Group type: EXPERIMENTAL
Intervention: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) supervised by a Registered Nurse
Number of subjects: 59
Study 17214754 — intervention group
Group type: EXPERIMENTAL
Intervention: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) with physical assistance from a Registered Nurse
Number of subjects: 59
Study 17214754 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59
Study 14667431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief stage‐matched interventions
Number of subjects: 4653
Study 14667431 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions helping populations progress two stages
Number of subjects: 4653
Study 11704162 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (50-200 mg/day)
Number of subjects: 164
Study 11704162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 9791141 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (indinavir, zidovudine, lamivudine)
Number of subjects: 316
Study 9791141 — intervention group
Group type: COMPARATOR
Intervention: Indinavir alone
Number of subjects: 316
Study 9791141 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine
Number of subjects: 316
Study 8162724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal BiPAP
Number of subjects: 9
Study 8162724 — intervention group
Group type: COMPARATOR
Intervention: Sham BiPAP
Number of subjects: 9
Study 2756516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuroxazide 400 mg twice a day
Number of subjects: 12
Study 2756516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuroxazide 1200 mg once a day
Number of subjects: 12
Study 2756516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31216092 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative structure‐retention relationship models for phthalic acid esters
Number of subjects: 23
Study 31216092 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models for retention times of new phthalic acid esters
Number of subjects: 23
Study 28160873 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL-SC) followed by Alendronate (ALN)
Number of subjects: 1139
Study 26008722 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM-high VF
Number of subjects: 151
Study 26008722 — intervention group
Group type: COMPARATOR
Intervention: NGT-high VF
Number of subjects: 151
Study 26008722 — intervention group
Group type: COMPARATOR
Intervention: NGT-normal VF
Number of subjects: 151